ASX-listed eHealth SaaS company Respiri (ASX:RSH) reports that world-class leading cardiac centre Arkansas Heart Hospital (AHH) has chosen its wheezo Remote Patient Management (RPM) program as an addition to the standard of care to help better manage CVD patients.
The wheezo RPM program has been chosen to aid CVD patients that also have Chronic Obstructive Pulmonary Disease (COPD), as well as improve health outcomes and reduce hospital re-admissions costs.
The company notes that the program was secured with its RPM partner Access Telehealth and will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring.
Utilisation of the RPM program is expected to commence at AHH immediately.
Speaking on the choosing of wheezo by Arkansas Heart Hospital, Respiri CEO, Marjan Mikel says: “Patients with cardiovascular disease are difficult to manage and often have numerous co-morbidities that further complicate their treatment.
“we are delighted that the Arkansas Heart, a preeminent cardiovascular organisation, has chosen to add the wheezo RPM program to the standard of care for the thousands of CVD patients with COPD under their care”
COPD is one such common complication and we are delighted that the Arkansas Heart, a preeminent cardiovascular organisation, has chosen to add the wheezo RPM program to the standard of care for the thousands of CVD patients with COPD under their care to improve health outcomes and reduce hospital re-admissions.”
The company also notes that RPM Current Procedural Terminology (CPT) reimbursement codes from this program will be processed through Centres for Medicare and Medicaid Services (CMS) and private insurers.
In addition, the use of the wheezo RPM program represents the first time that AHH will provide such as program focused on remote respiratory disease monitoring using the novel wheezo device to track and monitor patient physiologic data on hospital discharge.
As of 3:30pm (AWST) Respiri’s share price has increased by 18.42%.
Respiri is an ASX-listed international eHealth company that is leading the way in the development of innovative eHealth solutions that aim to improve the management of chronic and costly respiratory disorders such as asthma and COPD. The solutions created by the company have the potential to help transform the way physicians interact with respiratory patients while they are away from the clinic. The company’s wheezo is an FDA cleared Class 2 Medical Device which can be integrated into RPM programs.
Respiri announces that patient selection and recruitment for the full program will commence immediately.